Skip to search formSkip to main contentSkip to account menu

toceranib phosphate

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive… 
2018
2018
Efficacious therapies for measurable metastatic canine osteosarcoma (OSA) are generally lacking. Preliminary retrospective… 
2017
2017
Objectives The aim of the study was to determine the clinical benefit and adverse event profile of toceranib phosphate in the… 
2016
2016
While maintaining a standard toceranib dosage [2.75 mg kg(-1) , PO, every other day (EOD)], three dose-escalating CCNU cohorts up… 
Highly Cited
2013
Highly Cited
2013
BackgroundThe receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009 using a dose of 3.25… 
Highly Cited
2012
Highly Cited
2012
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate… 
2012
2012
Palladia(TM) (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI… 
2012
2012
Toceranib phosphate and piroxicam have individually demonstrated antineoplastic activity. Additionally, non-steroidal anti… 
Highly Cited
2009
Highly Cited
2009
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell…